Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Alnylam is making a $250 million investment in its Massachusetts manufacturing facility. The investment comes as the company begins to expand beyond rare disease treatments into more common conditions ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...